Login Register Cart 0
Generic placeholder image

Current Indian Science

Editor-in-Chief

ISSN (Print): 2210-299X
ISSN (Online): 2210-3007

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Platinum(II) Complexes of 3-Hydroxypyridine-2-Carboxaldehyde, N(4)-Methyl and N(4)-Pyrrolidinyl Thiosemicarbazones: Synthesis, Characterization, and Primary Anticancer Screening against HeLa Cells, and Molecular Docking

Author(s): Paras Nath Yadav*, Shivani Sharma, Motee Lal Sharma, Abdur Rauf, Umer Rahid and Yuba Raj Pokharel*

Volume 1, 2023

Published on: 25 January, 2023

Article ID: e010922208409 Pages: 9

DOI: 10.2174/2210299X01666220901114730

Price: $

Abstract

Background: Thiosemicarbazones are an important class of synthetic organic compounds exhibiting promising biological activities, including antiviral, antibacterial, antitubercular, antiprotozoal, antimalarial, antifungal, enzyme inhibitory, and antitumor. Different α-(N)-heterocyclic thiosemicarbazones are potent inhibitors of ribonucleotide reductase enzyme that play a critical role in the DNA synthesis; moreover, some have been found 1000-fold more potent than the clinical drug hydroxyl urea.

Objective: Different coordination complexes have been assessed for their efficacy to target MDR and surpass side effects associated with platinum drugs. In this work, we have prepared and investigated the anticancer potential of new platinum compounds of 3- hydroxy-2-formylpyridine thiosemicarbazones.

Methods: Novel Pt(II) complexes were synthesized and characterized by elemental analyses, FT-IR, 1H-NMR, UV-visible spectroscopy, and mass spectrometry. The in vitro anticancer activity of the synthesized compounds against HeLa cells by MTT assay was assessed. Protein-fixed and ligand-flexible docking studies were carried out using the Lamarckian genetic algorithm and Autodock 4.2 software.

Results: The IC50 values of compounds (3) and (4) through MTT screening against HeLa cells were found to be 107.16 μM and 132.13 μM, respectively. The binding energy value for the complex [Pt(HyPyMe)Cl] was -6.49 kcal/mol. While for complex, [Pt(HyPyPyrd)Cl] was found to have a binding energy value of -6.83 kcal/mol.

Conclusion: The spectroscopic and analytical data showed the mononuclear structures and square planar geometry of the Pt(II) complexes. The compounds exhibited moderate antineoplastic activity, and N(4)-methyl-substituted compound exhibited better anticancer activity. [Pt(HyPyMe)Cl] complex formed hydrogen bond interactions with guanine-6, guanine-7 and thiamine-8. While, [Pt(HyPyPyrd)Cl] interacted with guanine-7 and guanine-16 via hydrogen bond interaction.

Keywords: Antineoplastic activities, ESI-Mass spectrometry, 3-hydroxypyridine, platinum(ii) complexes, thiosemicarbazone , molecular docking.

[1]
WHO. International Agency for Research on Cancer. 2018.
[2]
Kostova, I. Platinum complexes as anticancer agents. Recent Patents Anticancer Drug Discov., 2006, 1(1), 1-22.
[http://dx.doi.org/10.2174/157489206775246458] [PMID: 18221023]
[3]
Remesh, A. Toxicities of anticancer drugs and its management. Int. J. Basic Clin. Pharmacol., 2012, 1(1), 2-12.
[http://dx.doi.org/10.5455/2319-2003.ijbcp000812]
[4]
Siwek, A.; Stączek, P.; Wujec, M.; Bielawski, K.; Bielawska, A.; Paneth, P. Cytotoxic effect and molecular docking of 4-ethoxycarbonylmethyl-1-(piperidin-4-ylcarbonyl)-thiosemicarbazide—a novel topoisomerase II inhibitor. J. Mol. Model., 2013, 19(3), 1319-1324.
[http://dx.doi.org/10.1007/s00894-012-1679-6] [PMID: 23187686]
[5]
Wei, L.; Easmon, J.; Nagi, R.K.; Muegge, B.D.; Meyer, L.A.; Lewis, J.S. 64Cu-azabicyclo[3.2.2]nonane thiosemicarbazone complexes: Radiopharmaceuticals for PET of topoisomerase II expression in tumors. J. Nucl. Med., 2006, 47(12), 2034-2041.
[PMID: 17138747]
[6]
Mishra, V.; Pandeya, S.N.; Pannecouque, C.; Witvrouw, M.; De Clercq, E. Anti-HIV activity of thiosemicarbazone and semicarbazone derivatives of (+/-)-3-menthone. Arch. Pharm. (Weinheim), 2002, 335(5), 183-186.
[http://dx.doi.org/10.1002/1521-4184(200205)335:5<183::AID-ARDP183>3.0.CO;2-U] [PMID: 12210774]
[7]
Shakya, B.; Yadav, P.N. Thiosemicarbazones as potent anticancer agents and their modes of action. Mini Rev. Med. Chem., 2020, 20(8), 638-661.
[http://dx.doi.org/10.2174/1389557519666191029130310] [PMID: 31660812]
[8]
Shakya, B.; Yadav, P.N.; Ueda, J.; Awale, S. Discovery of 2-pyridineformamide thiosemicarbazones as potent antiausterity agents. Bioorg. Med. Chem. Lett., 2014, 24(2), 458-461.
[http://dx.doi.org/10.1016/j.bmcl.2013.12.044] [PMID: 24380769]
[9]
Shakya, B.; Shahi, N.; Ahmad, F.; Yadav, P.N.; Pokharel, Y.R. 2-Pyridineformamide N(4)-ring incorporated thiosemicarbazones inhibit MCF-7 cells by inhibiting JNK pathway. Bioorg. Med. Chem. Lett., 2019, 29(13), 1677-1681.
[http://dx.doi.org/10.1016/j.bmcl.2019.04.031] [PMID: 31053506]
[10]
Enyedy, É.A.; Primik, M.F.; Kowol, C.R.; Arion, V.B.; Kiss, T.; Keppler, B.K. Interaction of Triapine and related thiosemicarbazones with iron(iii)/(ii) and gallium(iii): A comparative solution equilibrium study. Dalton Trans., 2011, 40(22), 5895-5905.
[http://dx.doi.org/10.1039/c0dt01835j] [PMID: 21523301]
[11]
Alomar, K.; Landreau, A.; Allain, M.; Bouet, G.; Larcher, G. Synthesis, structure and antifungal activity of thiophene-2,3-dicarboxaldehyde bis(thiosemicarbazone) and nickel(II), copper(II) and cadmium(II) complexes: Unsymmetrical coordination mode of nickel complex. J. Inorg. Biochem., 2013, 126, 76-83.
[http://dx.doi.org/10.1016/j.jinorgbio.2013.05.013] [PMID: 23792913]
[12]
Serda, M.; Kalinowski, D.S.; Rasko, N.; Potůčková, E.; Mrozek-Wilczkiewicz, A.; Musiol, R.; Małecki, J.G.; Sajewicz, M.; Ratuszna, A.; Muchowicz, A.; Gołąb, J.; Šimůnek, T.; Richardson, D.R.; Polanski, J. Exploring the anti-cancer activity of novel thiosemicarbazones generated through the combination of retro-fragments: Dissection of critical structure-activity relationships. PLoS One, 2014, 9(10), e110291.
[http://dx.doi.org/10.1371/journal.pone.0110291] [PMID: 25329549]
[13]
Finch, R.A.; Liu, M.C.; Cory, A.H.; Cory, J.G.; Sartorelli, A.C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): An inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul., 1999, 39(1), 3-12.
[http://dx.doi.org/10.1016/S0065-2571(98)00017-X] [PMID: 10470363]
[14]
Nutting, C.M.; van Herpen, C.M.L.; Miah, A.B.; Bhide, S.A.; Machiels, J.P.; Buter, J.; Kelly, C.; de Raucourt, D.; Harrington, K.J. Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. Ann. Oncol., 2009, 20(7), 1275-1279.
[http://dx.doi.org/10.1093/annonc/mdn775] [PMID: 19246715]
[15]
Zeidner, J.F.; Karp, J.E.; Blackford, A.L.; Smith, B.D.; Gojo, I.; Gore, S.D.; Levis, M.J.; Carraway, H.E.; Greer, J.M.; Ivy, S.P.; Pratz, K.W.; McDevitt, M.A. A phase II trial of sequential ribonucleotide reductase inhibition in aggressive myeloproliferative neoplasms. Haematologica, 2014, 99(4), 672-678.
[http://dx.doi.org/10.3324/haematol.2013.097246] [PMID: 24362550]
[16]
French, F.A.; Blanz, E.J., Jr The carcinostatic activity of alpha-(N)-heterocyclic carboxaldehyde thiosemicarbazones. II. 3-Hydroxypyridine-2-carboxaldehyde thiosemicarbazone. Cancer Res., 1966, 26(8), 1638-1640.
[PMID: 5923162]
[17]
Florea, A.M.; Büsselberg, D. Cisplatin as an anti-tumor drug: Cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel), 2011, 3(1), 1351-1371.
[http://dx.doi.org/10.3390/cancers3011351] [PMID: 24212665]
[18]
Lovejoy, D.B.; Jansson, P.J.; Brunk, U.T.; Wong, J.; Ponka, P.; Richardson, D.R. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redox-active copper complex that accumulates in lysosomes. Cancer Res., 2011, 71(17), 5871-5880.
[http://dx.doi.org/10.1158/0008-5472.CAN-11-1218] [PMID: 21750178]
[19]
Yadav, P.N.; Beveridge, R.E.; Blay, J.; Boyd, A.R.; Chojnacka, M.W.; Decken, A.; Deshpande, A.A.; Gardiner, M.G.; Hambley, T.W.; Hughes, M.J.; Jolly, L.; Lavangie, J.A.; MacInnis, T.D.; McFarland, S.A.; New, E.J.; Gossage, R.A. Platinum-oxazoline complexes as anti-cancer agents: Syntheses, characterisation and initial biological studies. MedChemComm, 2011, 2(4), 274-277.
[http://dx.doi.org/10.1039/c0md00211a]
[20]
Sharma, V.; Piwnica-Worms, D. Metal complexes for therapy and diagnosis of drug resistance. Chem. Rev., 1999, 99(9), 2545-2560.
[http://dx.doi.org/10.1021/cr980429x] [PMID: 11749491]
[21]
Mehta, P.K.; Joshi, B.; Yadav, P.N. Platinum (II) complex of 5-hydroxypyridine-2-carbaldehyde N(4)-ethylthiosemicarbazone: Synthesis, characterization and antineoplastic activity. J. Bangladesh Chem. Soc, 2015, 27(1&2), 132-138.
[22]
Shahi, N.; Pokhrel, P.; Thapa, R.S.; Pokharel, Y. R.; Yadav, P.N. Anticancer potency of 3-hydroxypyridine-2-carboxaldehyde N(4)-methyl and pyrrolidinylthiosemicarbazones and their Zn(II) complexes in PC3, HeLa, and DU145 cells through MTT assay and PI staining. Results Chem., 2021, 3, 100104.
[23]
Heinert, D.; Martell, A.E. Pyridoxine and pyridoxal analogs. II. Infrared spectra and hydrogen bonding. J. Am. Chem. Soc., 1959, 81(15), 3933-3943.
[http://dx.doi.org/10.1021/ja01524a031]
[24]
Rogolino, D.; Cavazzoni, A.; Gatti, A.; Tegoni, M.; Pelosi, G.; Verdolino, V.; Fumarola, C.; Cretella, D.; Petronini, P.G.; Carcelli, M. Anti-proliferative effects of copper(II) complexes with hydroxyquinoline-thiosemicarbazone ligands. Eur. J. Med. Chem., 2017, 128, 140-153.
[http://dx.doi.org/10.1016/j.ejmech.2017.01.031] [PMID: 28182987]
[25]
Demertzis, M.A.; Yadav, P.N.; Kovala-Demertzi, D. (II) complexes of the thiosemicarbazone and N-ethylthiosemicarbazone of 3-hydroxypyridine-2-carbaldehyde; Synthesis, properties and x-ray crystal structure. Helv. Chim. Acta, 2006, 89(9), 1959-1970.
[http://dx.doi.org/10.1002/hlca.200690187]
[26]
Karaküçük-İyidoğan, A.; Taşdemir, D.; Oruç-Emre, E.E.; Balzarini, J. Novel platinum(II) and palladium(II) complexes of thiosemicarbazones derived from 5-substitutedthiophene-2-carboxaldehydes and their antiviral and cytotoxic activities. Eur. J. Med. Chem., 2011, 46(11), 5616-5624.
[http://dx.doi.org/10.1016/j.ejmech.2011.09.031] [PMID: 21993152]
[27]
Gambino, D.; Otero, L.; Vieites, M.; Boiani, M.; González, M.; Baran, E.J.; Cerecetto, H. Vibrational spectra of palladium 5-nitrofuryl thiosemicarbazone complexes: Experimental and theoretical study. Spectrochim. Acta A Mol. Biomol. Spectrosc., 2007, 68(2), 341-348.
[http://dx.doi.org/10.1016/j.saa.2006.11.043] [PMID: 17321785]
[28]
Elsayed, S.A.; El-Hendawy, A.M.; Mostafa, S.I.; Jean-Claude, B.J.; Todorova, M.; Butler, I.S. Antineoplastic activity of new transition metal complexes of 6-methylpyridine-2-carbaldehyde-N(4)-ethylthiosemicarbazone: X-ray crystal structures of [VO2(mpETSC)] and [Pt(mpETSC)Cl]. Bioinorg. Chem. Appl., 2010, 2010(2), 149149.
[http://dx.doi.org/10.1155/2010/149149]
[29]
Reiss, A.; Mureseanu, M. Transition metal complexes with ligand containing thioamide moiety: Synthesis, characterization and antibacterial activities. J. Chil. Chem. Soc., 2012, 57(4), 1409-1414.
[http://dx.doi.org/10.4067/S0717-97072012000400016]
[30]
Bell, C.F.; Mortimore, G.R.; Reed, G.L. The1H NMR spectra of zinc complexes of pyridine-2-carbaldehyde 2′-pyridylhydrazone. Org. Magn. Reson., 1976, 8(1), 45-48.
[http://dx.doi.org/10.1002/mrc.1270080111]
[31]
Selbin, J.; Gutierrez, M.A. Cyclometallation. J. Organomet. Chem., 1981, 214(2), 253-259.
[http://dx.doi.org/10.1016/S0022-328X(00)86634-6]
[32]
Yadav, P.N.; Demertzis, M.A.; Kovala-Demertzi, D.; Castineiras, A.; West, D.X. Synthesis, solution and spectral studies of palladium(II) complexes with 2-hydroxyacetophenone N(3)-propylthiosemicar bazone. Crystal structure of a tripalladium complex. Inorg. Chim. Acta, 2002, 332(1), 204-209.
[http://dx.doi.org/10.1016/S0020-1693(02)00710-7]
[33]
Hernández, W.; Carrasco, F.; Vaisberg, A.; Spodine, E.; Manzur, J.; Icker, M.; Krautscheid, H.; Beyer, L. Synthesis, spectroscopic characterization, structural studies, and in vitro antitumor activities of pyridine-3-carbaldehyde thiosemicarbazone derivatives. J. Chem, 2020, 2020, 2960165.
[http://dx.doi.org/10.1155/2020/2960165]
[34]
Ali, A.Q.; Teoh, S.G.; Salhin, A.; Eltayeb, N.E.; Ahamed, M.B.K.; Majid, A.M.S.A. Synthesis of platinum(II) complexes of isatin thiosemicarbazones derivatives: In vitro anti-cancer and deoxyribose nucleic acid binding activities. Inorg. Chim. Acta, 2014, 416, 235-244.
[http://dx.doi.org/10.1016/j.ica.2014.03.029]
[35]
Finkielsztein, L.M.; Castro, E.F.; Fabián, L.E.; Moltrasio, G.Y.; Campos, R.H.; Cavallaro, L.V.; Moglioni, A.G. New 1-indanone thiosemicarbazone derivatives active against BVDV. Eur. J. Med. Chem., 2008, 43(8), 1767-1773.
[http://dx.doi.org/10.1016/j.ejmech.2007.10.023] [PMID: 18063227]
[36]
Vu, D.B.; Dang, T.B.; Synthesizing, N. (4)-substituted thiosemicarbazones and their structural characteristics. HCMUP J. Sci., 2014, 5, 12-19.
[37]
Kovala-Demertzi, D.; Demertzis, M.; Yadav, P.N.; Castiñeiras, A.; West, D.X. Preparation, spectral and structural characterization of (2-benzoylpyridine N(4)-methyl-N(4)-phenylthiosemicarbazonato) chloropalladium(II). Trans. Met. Chem. (Weinh.), 1999, 24(6), 642-647.
[http://dx.doi.org/10.1023/A:1006989117072]
[38]
Quang, D.T.; Do, V.D.; Kinh, C.D. UV-Vis spectra of some Platinum(II) complexes with thiosemicacbazonate ligands. Vietnam J. Chem., 2005, 43, 322-325.
[39]
Hernández, W.; Paz, J.; Vaisberg, A.; Spodine, E.; Richter, R.; Beyer, L. Synthesis, characterization, and in vitro cytotoxic activities of benzaldehyde thiosemicarbazone derivatives and their palladium(II) and Platinum(II) complexes against various human tumor cell lines. Bioinorg. Chem. Appl., 2008, 2008, 1-9.
[http://dx.doi.org/10.1155/2008/690952]
[40]
Ali, A.A.; Nimir, H.; Aktas, C.; Huch, V.; Rauch, U.; Schäfer, K.H.; Veith, M. Organoplatinum (II) complexes with 2-acetylthiophene thiosemicarbazone: Synthesis, characterization, crystal structures, and in vitro antitumor activity. Organometallics, 2012, 31(6), 2256-2262.
[http://dx.doi.org/10.1021/om201178q]
[41]
Matesanz, A.I.; Leitao, I.; Souza, P. Palladium(II) and platinum(II) bis(thiosemicarbazone) complexes of the 2,6-diacetylpyridine series with high cytotoxic activity in cisplatin resistant A2780cisR tumor cells and reduced toxicity. J. Inorg. Biochem., 2013, 125, 26-31.
[http://dx.doi.org/10.1016/j.jinorgbio.2013.04.005] [PMID: 23685347]
[42]
Tyagi, M.; Chandra, S. Synthesis, characterization and biocidal properties of platinum metal complexes derived from 2,6-diacetylpyridine (bis thiosemicarbazone). Open J. Inorg. Chem., 2012, 2(3), 41-48.
[http://dx.doi.org/10.4236/ojic.2012.23007]
[43]
Matesanz, A.I.; Souza, P. Novel cyclopalladated and coordination palladium and platinum complexes derived from α-diphenyl ethanedione bis(thiosemicarbazones): Structural studies and cytotoxic activity against human A2780 and A2780cisR carcinoma cell lines. J. Inorg. Biochem., 2007, 101(10), 1354-1361.
[http://dx.doi.org/10.1016/j.jinorgbio.2007.05.013] [PMID: 17640735]
[44]
Zhou, J.; Kang, Y.; Chen, L.; Wang, H.; Liu, J.; Zeng, S. The drug-resistance mechanisms of five platinum-based antitumor agents. Front. pharmacol., 2020, 11, 1-17.
[http://dx.doi.org/10.3389/fphar.2020.00343] [PMID: 32265714]
[45]
Nawaz, H.; Waseem, A.; Zia-ur-Rehman; Nafees, M.; Arshad, M.N.; Rashid, U. Synthesis, characterization, cytotoxicity and computational studies of new phosphine and carbodithioate based palladium(II) complexes. Appl. Organomet. Chem., 2017, 31(11), e3771.
[http://dx.doi.org/10.1002/aoc.3771]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy